Compare First Horizon Corporation Common Stock (FHN) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Horizon Corporation Common Stock vs Vertex Pharmaceuticals Incorporated — how do they compare? First Horizon Corporation Common Stock trades at $22.63 (market cap $10.79B), while Vertex Pharmaceuticals Incorporated trades at $504.87 (market cap $122.98B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 11.4× First Horizon Corporation Common Stock's market cap, and First Horizon Corporation Common Stock pays a 2.99% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold First Horizon Corporation Common Stock for 0 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| FHN | VRTX | |
|---|---|---|
Market Cap | $10.79B | $122.98B |
Volume | 8,579,466 | 1,155,743 |
Sector | Financials | Health |
52-Week High | $26.23 | $557.96 |
52-Week Low | $19.94 | $407.90 |
Typical Hold Time | 0 Days | 120 Days |
Enterprise Value | $14.10B | $117.11B |
Dividend Yield | 2.99% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
First Horizon (FHN) trades at $22.77, down 1.26% on the day, with a neutral technical outlook. The stock shows strong fundamentals, including a P/E of 10.95 and net income margin of 30.87% for 2026, supported by three consecutive quarterly earnings beats. Recent news highlights executive recognitions and upcoming Q3 2026 earnings on October 15, 2026.
The outlook is positive given robust profitability, analyst consensus price target of $27.44 (20.5% upside), and no sell ratings. Risks include high debt-to-asset ratio of 1.81 and macroeconomic sensitivity. Earnings growth remains the key catalyst for further upside, with investor focus on Q3 results.
Vertex Pharmaceuticals (VRTX) trades at $498.50, down 1.68% amid mixed technical signals. The stock shows strong fundamentals with $12B revenue, 35% net margins, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Technical indicators show bearish momentum with support at $496 and resistance at $512.
Outlook remains positive with 86% analyst buy ratings and $573.50 price target. Key risks include clinical trial outcomes and competitive pressures. The company's expanding pipeline and profitability provide upside potential, though near-term volatility may persist around key technical levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About First Horizon Corporation Common Stock
First Horizon Corporation is the holding company for First Horizon Bank, a regional financial services provider operating roughly 460 branches across 11 states in southeastern US. It offers commercial, consumer, private banking, wealth management, and capital markets services.
Read more on FHN →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
